15 Best Growth Stocks to Invest in for the Next 5 Years

Page 7 of 13

7. Actinium Pharmaceuticals, Inc. (NYSE:ATNM)

Upside potential as of June 24, 2025: 195.02%

During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400.

The data indicated that the leading drug demonstrated superior cancer cell killing in contrast to Xtandi (enzalutamide) and greater efficacy than not only Pluvicto (177Lu-PSMA-617) but also Ac-225-PSMA-617 in both laboratory and animal models. As the Actinium’s Chairman and CEO, Sandesh Seth, stated,

“ATNM-400 is the ideal cornerstone of our emerging solid tumor pipeline.”

We have seen how Xtandi, developed by Astellas and Pfizer, secured $5.9 billion in sales in 2024, with Novartis’s Pluvicto generating $1.4 billion in the same period. Since ATNM-400 is the potential monotherapy or is complementary to the existing prostate cancer treatments, we have good reason to believe that the drug will be a turnaround point for Actinium Pharmaceuticals, Inc. (NYSE:ATNM).

Actinium Pharmaceuticals, Inc. (NYSE:ATNM), based in New York, develops antibody radiation conjugates and other targeted radiotherapies to address the failures of the current oncology therapies. With two clinical-stage product candidates, Actimab-A and Iomab-ACT, the giant aims to build a hospital-focused radiotherapeutics company.

Page 7 of 13